87 -2 (88) 2026 - Miraxmеdova Sh.T., Kayumova D.T. - FEATURES OF MENSTRUAL FUNCTION AS A RISK FACTOR FOR THE FORMATION OF POLYCYSTIC OVARIAN SYNDROME IN ADOLESCENTS

FEATURES OF MENSTRUAL FUNCTION AS A RISK FACTOR FOR THE FORMATION OF POLYCYSTIC OVARIAN SYNDROME IN ADOLESCENTS

Miraxmеdova Sh.T. - Tashkent State Medical University

Kayumova D.T. - Tashkent State Medical University

Xodjaеva N.X. - Tashkent State Medical University

Salimova N.Dj. - Tashkent State Medical University

Resume

Polycystic ovary syndrome (PCOS) in adolescents remains one of the most debated challenges in contemporary gynecologic endocrinology. The classical Rotterdam criteria (2003), designed primarily for the adult population, do not fully capture the physiological characteristics of the pubertal period. The aim of the study was to perform a comprehensive evaluation of menstrual function in adolescent girls and to identify risk factors for the development of PCOS. A total of 182 girls aged 13–17 years were examined. Based on the identified features—hirsutism, menstrual irregularities, and excess body weight—the criteria and the prevalence of combined manifestations (ranging from 1.1% to 7.2%) were determined among adolescents, which may indicate an increased likelihood of developing PCOS in reproductive age

Key words: polycystic ovary syndrome, adolescent girls

First page

447

Last page

451

For citation:Miraxmеdova Sh.T., Kayumova D.T., Xodjaеva N.X., Salimova N.Dj. - FEATURES OF MENSTRUAL FUNCTION AS A RISK FACTOR FOR THE FORMATION OF POLYCYSTIC OVARIAN SYNDROME IN ADOLESCENTS//New Day in Medicine 2(88)2026 447-451 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Goodman N.F., Cobin R.H., Futterweit W. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 1. Endocr. Pract. 2015;21(11):1291–300.
2. Lause M., Kamboj A., Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl. Pediatr. 2017;6(4):300–312.
3. Munro M.G., Balen A.H., Cho S.; FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility. The FIGO Ovulatory Disorders Classification System. Fertil. Steril. 2022;118(4):768-786
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Fertil. Steril. 2004;81:19-25.
5. Rosenfield R.L. Perspectives on the international recommendations for the diagnosis and treatment of polycystic ovary syndrome in adolescence. J. Pediatr. Adolesc. Gynecol. 2020;33(5):445-447.
6. Peña A.S., Witchel S.F., Hoeger K.M. Adolescent polycystic ovary syndrome according to the international evidencebased guideline. BMC Med. 2020;18(1):72.
7. Teede H., Misso M., Tassone E.C. Anti-Müllerian hormone in PCOS: a review informing international guidelines. Trends Endocrinol. Metab. 2019;30(7):467-478.
8. Teede H.J., Misso M.L., Costello M.F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2
9. Teede H.J., Misso M.L., Costello M.F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018;110(3):364-379.

   file

   download